Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 4/20 | 0.42 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 2/20 | 0.35 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.32 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL92987 | 0.74 | CCNE2 (0.41) | ESR1ALDH1A1SMN1; SMN2KMT2AKDM4E | |
| SCHEMBL19147198 | 0.72 | CYP2C9 (0.38) | ALDH1A1SMN1; SMN2KMT2ACYP2C9CYP3A4 | |
| SCHEMBL5586804 | 0.70 | LTA4H (0.44) | THRATHRBESR1SMN1; SMN2LTA4H | |
| SCHEMBL15322103 | 0.69 | KDM4E (0.42) | ESR1ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL4558607 | 0.69 | NR5A1 (0.41) | THRATHRBESR1KMT2AMEN1 | |
| SCHEMBL28974964 | 0.69 | LTA4H (0.42) | THRATHRBESR1SMN1; SMN2LTA4H | |
| SCHEMBL12833107 | 0.67 | THRA (0.57) | THRATHRBALDH1A1SMN1; SMN2POLB | |
| SCHEMBL5588832 | 0.67 | HPGD (0.44) | THRATHRBESR1ALDH1A1LTA4H | |
| SCHEMBL16069695 | 0.67 | LTA4H (0.41) | THRATHRBESR1ALDH1A1LTA4H | |
| Bromide SCHEMBL25341248 | 0.66 | NQO2 (0.36) | ALDH1A1KMT2AMEN1KDM4EPDXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | HETERO RESEARCH FOUNDATION (IN) | 2017-11-23 | — | — | US | disclosed |
| US-20170267693-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-21 | — | — | US | disclosed |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-14 | — | — | US | disclosed |
| US-20170253616-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-09-07 | — | — | US | disclosed |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170209454-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-07-27 | — | — | US | disclosed |
| EP-3187225-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2017-07-05 | — | — | EP | disclosed |
| EP-3187226-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | VIIV Healthcare Company (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170145033-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-05-25 | — | — | US | disclosed |
| US-9650394-B2 | Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| EP-2465580-A1 | Polycyclic carbamoylpyridone derivatives having hiv integrase inhibitory activity | Glaxosmithkline LLC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8188271-B2 | Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-05-29 | — | — | US | disclosed |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | GLAXOSMITHKLINE LLC | 2012-05-10 | — | — | US | disclosed |
| US-8129385-B2 | Substituted 5-hydroxy-3,4,6,9,9a, 10-hexanhydro-2h-1-oxa04a,8a-diaza-anthracene-6,10-dioness | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-7858788-B2 | Bicyclic carbamoylpyridone derivative having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | VIIV HEALTHCARE COMPANY | 2009-12-24 | — | — | US | disclosed |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| EP-1950212-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITORY ACTIVITY ON HIV INTEGRASE | Shionogi Co., Ltd. (JP) | 2008-07-30 | — | — | EP | disclosed |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| EP-1852434-A1 | BICYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITING ACTIVITY | Shionogi Co., Ltd. (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145033-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2844/4885THRB 2457/4885ESR1 142/4885 |
| US-20080161271-A1 | Bicyclic Carbamoylpyridone Derivative Having Hiv Integrase Inhibitory Activity | NR4A1, HAT1, NR4A2 | THRA 2673/4885THRB 2070/4885ESR1 119/4885 |
| US-20170209454-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2844/4885THRB 2457/4885ESR1 142/4885 |
| US-20170334858-A1 | PROCESS FOR THE PREPARATION OF INTERMEDIATE OF DOLUTEGRAVIR | CYP3A4, DHPS, MVD | THRA 4790/4885THRB 4709/4885ESR1 3319/4885 |
| US-20120115875-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2876/4885THRB 2517/4885ESR1 146/4885 |
| US-20170260203-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2844/4885THRB 2457/4885ESR1 142/4885 |
| US-20090143356-A1 | Polycylclic Carbamoylpyridone Derivative Having HIV Integrase Inhibitory Acitvity | CDK20, CYP4A22, CDK10 | THRA 4131/4885THRB 3733/4885ESR1 828/4885 |
| US-20170253616-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2761/4885THRB 2427/4885ESR1 139/4885 |
| US-20170224695-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NCOA4, NR4A1, NR4A2 | THRA 3081/4885THRB 2700/4885ESR1 131/4885 |
| US-20090318421-A1 | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity | NR4A1, NCOA4, NR4A2 | THRA 2876/4885THRB 2517/4885ESR1 146/4885 |
| US-20170267693-A1 | POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY | NR4A1, NCOA4, NR4A2 | THRA 2844/4885THRB 2457/4885ESR1 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.